SCHEMBL6389727

SCHEMBL6389727

O=C(NC1CCSC1=O)c1cnc(NNC(=S)NC2c3ccccc3CSc3ccccc32)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
PKM P14618 1/20 0.41
POLB P06746 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
PSMD14 O00487 1/20 0.40
USP2 O75604 1/20 0.40
PLA2G1B P04054 1/20 0.40
ALPL P05186 1/20 0.40
MMP2 P08253 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
PTPN7 P35236 1/20 0.40
DUSP3 P51452 1/20 0.40
BLM P54132 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6385743 1.00 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6386400 0.92 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6386238 0.92 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL4701490 0.92 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6385238 0.88 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6391808 0.87 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6385891 0.86 ALDH1A1 (0.40) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6385898 0.86 ALDH1A1 (0.40) ALDH1A1CYP1A2CYP3A4CYP2C19PKM
SCHEMBL6385280 0.85 GAA (0.38) ALDH1A1CYP2C19KMT2ATDP1MEN1
SCHEMBL6387583 0.84 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP3A4CYP2C19PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245503-A1 Therapeutic heterocycles ASTRAZENECA AB (SE) 2005-11-03 US claimed
US-20050245503-A1 Therapeutic heterocycles ASTRAZENECA AB (SE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245503-A1 Therapeutic heterocycles OPRK1, RECQL, OPRM1 ALDH1A1 2117/4885CYP1A2 139/4885CYP3A4 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.